Survodutide hits 13.1% weight loss in Phase III obesity-T2D trial
Boehringer Ingelheim has reported that survodutide, a glucagon/GLP-1 receptor dual agonist licensed from Zealand Pharma, achieved up to 13.1% mean body weight reduction versus 3.1% on placebo after 76 weeks in adults with obesity and type 2 diabetes, with both co-primary endpoints met in the Phase III SYNCHRONIZE-2 trial. Up to 79.3% of participants on the drug achieved a body weight reduction of at least 5%, compared with 32.7% on placebo. The results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan and simultaneously published in the New England Journal of Medicine.
The trial enrolled 755 adults and used weekly injections of survodutide at doses of 3.6 mg or 6.0 mg. Weight reduction in a type 2 diabetes population is considered clinically harder to achieve than in those without the condition, which the companies say lends particular weight to the magnitude of the results. David Kendall, Chief Medical Officer of Zealand Pharma, said the data "add to the growing body of evidence from the broad SYNCHRONIZE program, further reinforcing the novel mechanism of survodutide and its ability to potentially address not only obesity, but also the underlying disease drivers and associated metabolic health consequences."
Cardiometabolic secondary endpoints
Beyond weight reduction, secondary endpoint data showed meaningful improvements across markers of cardiometabolic health. Participants on survodutide experienced a reduction of up to 1.21% in HbA1c from a baseline of 7.4%, versus a 0.03% reduction in the placebo arm. Waist circumference fell by 11.1 cm on the drug against 3.5 cm on placebo, and up to 29.5% of treated patients reverted to normoglycemia (HbA1c below 5.7%), compared with 4.0% on placebo. Improvements in insulin sensitivity, as measured by fasting glucose and HOMA-IR, were also reported. Separately, a body composition sub-study from SYNCHRONIZE-1, in people without T2D, showed that muscle accounted for no more than 10% of total tissue lost and that reductions in visceral and liver fat appeared largely independent of the degree of overall weight reduction achieved.
Gastrointestinal adverse events, including nausea, vomiting, diarrhoea, and constipation, were the most commonly reported side effects, consistent with the GLP-1 class profile. The treatment discontinuation rate due to GI events was 18% on survodutide versus 1.2% on placebo, with most discontinuations occurring during dose escalation. Boehringer has noted that upcoming trials will allow more flexible, patient-centred titration to improve tolerability.
Competitive landscape and what comes next
The GLP-1 and dual-agonist weight-management market has expanded rapidly, with semaglutide and tirzepatide firmly established as approved standards. Survodutide's glucagon receptor component differentiates it mechanistically by targeting liver fat more directly, which the SYNCHRONIZE-1 sub-study data appear to support. Whether that translates into a commercially distinct profile will depend partly on cardiovascular outcomes data. Boehringer expects to present results from SYNCHRONIZE-CVOT, its cardiovascular outcomes trial, later in 2026, a readout that will be closely watched given the cardiovascular benefits already attributed to GLP-1-class agents.
Survodutide also holds FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis (MASH) and is being evaluated in the LIVERAGE Phase III programme for that indication, broadening the commercial opportunity substantially beyond obesity alone. A dedicated Phase III trial, SYNCHRONIZE-T2D, has also been initiated to evaluate glycaemic control in adults managing T2D with diet, exercise, or existing diabetes medications including insulin. Regulatory submissions will depend on the totality of data from this programme, and no filing timelines have been disclosed.